S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.10
+360.20
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
18.24
+1.56
+9.35%
CAPR · Capricor Therapeutics, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Capricor Therapeutics Inc (CAPR)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$5.87
-0.74
(-11.13%)
● At close: October 21 at 4:00:00 PM EDT
$5.90
+0.02
(+0.34%)
Overnight:
2:28:37 AM EDT
DAY'S RANGE
$5.87
$5.79
$6.67
52-WEEK RANGE
$5.87
$2.96
$40.37
What's happening
- CAPR is down 11.13% today, trading at $5.87. — Live quote
- Volume today (170,745) is well below its 3-month average of 5,447,750. (Finnhub fundamentals)
- Reports earnings on 2026-11-17, 26 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.70 actual vs. $-0.60 estimated (-16.3%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 3
Buy 6
Hold 7
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (16 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
CAPR
-77.10%
vs S&P 500
-89.67%
1-YEAR RETURN
CAPR
+5.76%
vs S&P 500
-8.80%
6-MONTH RETURN
CAPR
-81.14%
3-MONTH RETURN
CAPR
-66.10%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.70
Est. $-0.60
MISS -16.3%
2026-04-26 (Q1 2026)
$-0.59
Est. $-0.54
MISS -8.8%
2026-01-26 (Q4 2025)
$-0.62
Est. $-0.55
MISS -12.6%
2025-10-26 (Q3 2025)
$-0.54
Est. $-0.56
BEAT +3.3%
Valuation Measures & Ratios
Enterprise Value4$341.8M
Forward P/E5—
PEG Ratio6-0.05
Price / Sales (TTM1)16.29
Price / Book75.66
EV4 / Revenue15.35
EV4 / EBITDA697.48
Profit Margin-181.71%
Operating Margin-191.13%
Return on Equity (ROE8)-56.60%
Return on Assets (ROA9)-43.97%
Avg Volume (3M)5,447,750
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $1.40B | $1.75B | $327.2M | $150.2M | $14.6M |
| P/E | -11.18 | -16.06 | -3.74 | -2.03 | -0.25 |
| Price/Book | 5.68 | 6.27 | 3.90 | 1.43 | 0.11 |
| EV/EBITDA | -10.47 | -14.43 | -3.41 | — | — |
| ROE | -50.83% | -39.04% | -104.25% | -70.36% | -45.24% |
| ROA | -33.94% | -33.35% | -69.15% | -55.30% | -37.55% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short18,825,352
Change from Prior Settlement-4.35%
% of Float—
Days to Cover (Short Ratio)4.52
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +5.8%. Finnhub market metrics ↗
Potential concerns
- Net profit margin is -181.7%. Finnhub fundamentals ↗
- Latest SEC filing is Form 8-K, filed 2026-08-24; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on CAPR
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $2.3M | $4.0M | $4.9M |
| Operating income | -$42.9M | -$36.8M | -$26.3M | -$27.7M | -$25.0M | -$13.0M | -$11.6M | -$10.3M |
| Net income | -$40.7M | -$33.9M | -$24.6M | -$25.9M | -$24.4M | -$12.6M | -$11.0M | -$9.8M |
| EPS (diluted) | $-0.70 | $-0.59 | $-0.54 | $-0.57 | $-0.53 | $-0.38 | $-0.35 | $-0.31 |
| EPS (basic) | $-0.70 | $-0.59 | $-0.54 | $-0.57 | $-0.53 | $-0.38 | $-0.35 | $-0.31 |
| Operating margin | — | — | — | — | — | -$575 | -$292 | -$209 |
| Net margin | — | — | — | — | — | -$555 | -$277 | -$200 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $368.7M | $326.3M | $355.9M | $126.4M | $133.6M | $153.8M | $170.5M | $93.0M |
| Total liabilities | $122.5M | $47.6M | $50.2M | $42.6M | $28.6M | $26.1M | $25.0M | $24.7M |
| Stockholders' equity | $246.2M | $278.7M | $305.8M | $83.9M | $105.0M | $127.6M | $145.5M | $68.3M |
| Total current assets | $242.1M | $283.1M | $322.9M | $101.0M | $124.1M | $146.3M | $163.4M | $85.8M |
| Total current liabilities | $33.0M | $33.6M | $35.8M | $28.1M | $28.4M | $22.3M | $21.0M | $20.5M |
| Cash & equivalents | $20.9M | $105.4M | $287.8M | $19.5M | $23.2M | $28.8M | $11.3M | $68.4M |
| Marketable securities (current) | — | — | — | $79.1M | $99.6M | $116.0M | $140.2M | $16.7M |
| Property, plant & equipment | $36.3M | $28.5M | $18.3M | $11.1M | $8.0M | $6.1M | $5.6M | $5.3M |
| Goodwill | — | — | — | — | — | — | — | — |
| Intangible assets | — | — | — | — | — | — | — | — |
| Other non-current assets | — | — | — | — | — | — | — | — |
| Accounts payable | $3.1M | $3.9M | $1.7M | $2.7M | $4.8M | $5.3M | $3.3M | — |
| Accrued liabilities | $16.4M | $10.5M | $15.6M | $9.9M | $7.4M | $4.2M | $4.9M | — |
| Deferred revenue (current) | $12.0M | $12.0M | $12.0M | $12.0M | $12.0M | $12.0M | $12.0M | $13.1M |
| Other current liabilities | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $58.1K | $57.7K | $57.4K | $45.7K | $45.7K | $45.7K | $45.6K | $40.3K |
| Retained earnings | -$379.6M | -$338.8M | -$304.9M | -$274.7M | -$250.1M | -$224.2M | -$199.8M | -$192.7M |
| Accumulated other comprehensive income (loss) | -$163.5K | -$253.7K | $283.2K | $844.1K | $1.4M | $1.8M | $1.0M | $96.2K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$31.5M | -$29.3M | -$23.6M | -$19.7M | -$20.1M | -$6.4M | -$14.8M | -$11.6M |
| Investing cash flow | -$48.8M | -$154.6M | $43.1M | $16.0M | $14.5M | $23.9M | -$123.4M | $2.0M |
| Financing cash flow | -$4.2M | $1.5M | $248.8M | $7.0K | $19.6K | $50.4K | $81.1M | $67.3M |
| Free cash flow | -$35.5M | -$34.4M | -$25.2M | -$19.7M | -$20.4M | -$7.3M | -$15.3M | -$11.7M |
| Capital expenditures | $4.1M | $5.1M | $1.7M | $55.8K | $287.7K | $896.0K | $488.8K | $9.1K |
| Depreciation & amortization | $561.8K | $534.7K | $502.6K | $494.7K | $486.3K | $405.4K | $375.7K | $361.2K |
| Share-based compensation | — | — | — | — | — | — | $2.3M | $2.1M |
| Change in accounts payable | — | — | — | — | — | — | — | — |
| Purchases of investments | $75.9M | $174.9M | $15.0M | $58.2M | $60.0M | $18.2M | $139.4M | $19.8M |
| Other investing activities | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — |
| Debt issued | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $0 | $22.3M | $25.2M | $2.6M | $244.9K |
| Operating income | -$108.1M | -$42.6M | -$24.1M | -$29.7M | -$20.9M |
| Net income | -$105.0M | -$40.5M | -$22.3M | -$29.0M | -$20.0M |
| EPS (diluted) | $-2.26 | $-1.15 | $-0.83 | $-1.18 | $-0.87 |
| EPS (basic) | $-2.26 | $-1.15 | $-0.83 | $-1.18 | $-0.87 |
| Operating margin | — | -$191 | -$96 | -$1.2K | -$8.5K |
| Net margin | — | -$182 | -$89 | -$1.1K | -$8.2K |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Mar '22 |
|---|---|---|---|---|---|
| Total assets | $355.9M | $170.5M | $58.7M | $50.1M | — |
| Total liabilities | $50.2M | $25.0M | $36.1M | $38.3M | — |
| Stockholders' equity | $305.8M | $145.5M | $22.6M | $11.8M | — |
| Total current assets | $322.9M | $163.4M | $50.9M | $42.9M | — |
| Total current liabilities | $35.8M | $21.0M | $31.3M | $23.6M | — |
| Cash & equivalents | $287.8M | $11.3M | $14.7M | $9.6M | — |
| Marketable securities (current) | — | $140.2M | $24.8M | $31.8M | — |
| Property, plant & equipment | $18.3M | $5.6M | $5.6M | $4.6M | — |
| Goodwill | — | — | — | — | — |
| Intangible assets | — | — | — | — | — |
| Other non-current assets | — | — | — | — | — |
| Accounts payable | $1.7M | $3.3M | — | — | — |
| Accrued liabilities | $15.6M | $4.9M | — | — | — |
| Deferred revenue (current) | $12.0M | $12.0M | $24.3M | $18.0M | $30.0M |
| Other current liabilities | — | — | $27.5K | $89.2K | — |
| Common stock & paid-in capital | $57.4K | $45.6K | $31.1K | $25.2K | — |
| Retained earnings | -$304.9M | -$199.8M | -$159.4M | -$137.1M | — |
| Accumulated other comprehensive income (loss) | $283.2K | $1.0M | $235.8K | $105.2K | — |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$69.8M | -$40.0M | -$25.6M | $4.9M | -$16.8M |
| Investing cash flow | $97.5M | -$116.2M | $5.1M | -$35.1M | -$1.2M |
| Financing cash flow | $248.9M | $152.8M | $25.6M | $4.9M | $20.2M |
| Free cash flow | -$72.7M | -$41.2M | -$26.9M | $2.9M | -$18.0M |
| Capital expenditures | $2.9M | $1.2M | $1.3M | $2.0M | $1.2M |
| Depreciation & amortization | $1.9M | $1.4M | $1.1M | $533.1K | $245.7K |
| Share-based compensation | — | $9.8M | $7.4M | $4.5M | $3.0M |
| Change in accounts payable | — | — | — | — | — |
| Purchases of investments | $151.4M | $208.4M | $97.4M | $114.2M | $0 |
| Other investing activities | — | — | — | — | — |
| Share repurchases | — | — | — | — | — |
| Debt issued | — | — | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding CAPR as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Source: Business Quant SEC Form 13F · report period 2026-06-30 · 30 filers
Held by These Filers58.9%
Shares Outstanding58,108,989
| Filer | Shares | Value | % Out | Qtr Change | Filed |
|---|---|---|---|---|---|
| BlackRock, Inc. | 4,145,061 | $99.8M | 7.13% | +21.1% | 2026-08-07 |
| TANG CAPITAL MANAGEMENT LLC | 4,099,900 | $98.7M | 7.06% | +20.6% | 2026-08-14 |
| MONTANOVA CAPITAL, LLC | 4,092,784 | $98.6M | 7.04% | +7.2% | 2026-08-14 |
| State Street Corp | 3,397,150 | $81.8M | 5.85% | +55.7% | 2026-08-07 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2,297,674 | $55.3M | 3.95% | +13.3% | 2026-06-30 |
| Goldman Sachs Group Inc | 1,578,131 | $38.0M | 2.72% | +73.0% | 2026-08-14 |
| RA CAPITAL MANAGEMENT, L.P. | 1,507,844 | $36.3M | 2.59% | +0.0% | 2026-08-14 |
| Boxer Capital Management, LLC | 1,395,156 | $33.6M | 2.40% | +136.5% | 2026-08-14 |
| GEODE CAPITAL MANAGEMENT, LLC | 1,372,286 | $33.0M | 2.36% | +22.7% | 2026-08-12 |
| FMR LLC | 1,137,730 | $27.4M | 1.96% | +47.3% | 2026-08-13 |
| CITADEL ADVISORS LLC | 814,444 | $19.6M | 1.40% | +51.0% | 2026-08-14 |
| Soleus Capital Management, L.P. | 761,737 | $18.3M | 1.31% | +0.0% | 2026-08-11 |
| Morgan Stanley | 684,515 | $16.5M | 1.18% | +61.5% | 2026-08-11 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 636,087 | $15.3M | 1.09% | +67.7% | 2026-06-30 |
| UBS Group AG | 619,661 | $14.9M | 1.07% | +66.6% | 2026-08-13 |
| DG Capital Management, LLC | 611,595 | $14.7M | 1.05% | +56.0% | 2026-08-12 |
| Ikarian Capital, LLC | 604,215 | $14.5M | 1.04% | +14.4% | 2026-08-14 |
| Northern Trust Corp | 503,532 | $12.1M | 0.87% | +20.6% | 2026-08-12 |
| BALYASNY ASSET MANAGEMENT L.P. | 486,836 | $11.7M | 0.84% | +63.8% | 2026-08-13 |
| J. Goldman & Co LP | 427,321 | $10.3M | 0.74% | -21.1% | 2026-08-14 |
| Jones Hill Capital LP | 420,751 | $10.1M | 0.72% | -53.7% | 2026-08-13 |
| MERCER GLOBAL ADVISORS INC /ADV | 402,731 | $9.7M | 0.69% | -0.1% | 2026-08-11 |
| VANGUARD FIDUCIARY TRUST CO | 372,539 | $9.0M | 0.64% | +16.4% | 2026-06-30 |
| Jpmorgan Chase & Co | 362,501 | $8.7M | 0.62% | +5.5% | 2026-08-12 |
| GROUP ONE TRADING LLC | 272,609 | $6.6M | 0.47% | +114.4% | 2026-08-13 |
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-12-19 to 2026-06-25
Recent transactions
- Insiders have net sold 100,000 shares over the last 182 days, across 0 purchases and 8 sales.
- Most recent: Krasney Karen (EVP, GENERAL COUNSEL) — Option exercise of 24,100 shares on 2026-06-25.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)100,000 sh(8 txns)
Net Shares-100,000
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Krasney Karen | EVP, GENERAL COUNSEL | Option exercise | 2026-06-25 | 24,100 |
| Bergmann Anthony | CHIEF FINANCIAL OFFICER | Option exercise | 2026-06-25 | 24,100 |
| Litvack Frank | Reporting person | Option exercise | 2026-05-13 | 3,937 |
| Sabar Karimah Es | Reporting person | Option exercise | 2026-04-02 | 7,529 |
| DUNBAR GEORGE W JR | Reporting person | Option exercise | 2025-12-19 | 3,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-06-25 | Krasney Karen | EVP, GENERAL COUNSEL | Option exercise | 24,100 | $3.18 |
| 2026-06-25 | Krasney Karen | EVP, GENERAL COUNSEL | Open market sale | 24,100 | $30.38 |
| 2026-06-25 | Bergmann Anthony | CHIEF FINANCIAL OFFICER | Option exercise | 24,100 | $3.18 |
| 2026-06-25 | Bergmann Anthony | CHIEF FINANCIAL OFFICER | Open market sale | 24,100 | $30.38 |
| 2026-06-24 | Krasney Karen | EVP, GENERAL COUNSEL | Option exercise | 400 | $3.18 |
| 2026-06-24 | Krasney Karen | EVP, GENERAL COUNSEL | Open market sale | 400 | $30.00 |
| 2026-06-24 | Bergmann Anthony | CHIEF FINANCIAL OFFICER | Option exercise | 400 | $3.18 |
| 2026-06-24 | Bergmann Anthony | CHIEF FINANCIAL OFFICER | Open market sale | 400 | $30.00 |
| 2026-06-22 | Krasney Karen | EVP, GENERAL COUNSEL | Option exercise | 500 | $3.18 |
| 2026-06-22 | Krasney Karen | EVP, GENERAL COUNSEL | Open market sale | 500 | $30.00 |
| 2026-06-22 | Bergmann Anthony | CHIEF FINANCIAL OFFICER | Option exercise | 500 | $3.18 |
| 2026-06-22 | Bergmann Anthony | CHIEF FINANCIAL OFFICER | Open market sale | 500 | $30.00 |
| 2026-05-18 | Bergmann Anthony | CHIEF FINANCIAL OFFICER | Option exercise | 3,000 | $1.39 |
| 2026-05-13 | Litvack Frank | Reporting person | Option exercise | 3,937 | $1.39 |
| 2026-05-01 | Krasney Karen | EVP, GENERAL COUNSEL | Option exercise | 25,000 | $3.18 |
| 2026-05-01 | Krasney Karen | EVP, GENERAL COUNSEL | Open market sale | 25,000 | $31.70 |
| 2026-05-01 | Bergmann Anthony | CHIEF FINANCIAL OFFICER | Option exercise | 25,000 | $3.18 |
| 2026-05-01 | Bergmann Anthony | CHIEF FINANCIAL OFFICER | Open market sale | 25,000 | $31.70 |
| 2026-04-02 | Sabar Karimah Es | Reporting person | Option exercise | 7,529 | $3.18 |
| 2026-04-02 | Sabar Karimah Es | Reporting person | Open market sale | 7,529 | $32.00 |
| 2026-04-01 | Sabar Karimah Es | Reporting person | Option exercise | 53,735 | $4.86 |
| 2026-04-01 | Sabar Karimah Es | Reporting person | Open market sale | 53,735 | $31.03 |
| 2026-03-31 | Krasney Karen | EVP, GENERAL COUNSEL | Option exercise | 693 | $1.39 |
| 2026-03-31 | Krasney Karen | EVP, GENERAL COUNSEL | Option exercise | 21,488 | $3.74 |
| 2026-03-31 | Krasney Karen | EVP, GENERAL COUNSEL | Option exercise | 2,819 | $3.18 |
| 2026-03-31 | Krasney Karen | EVP, GENERAL COUNSEL | Open market sale | 25,000 | $30.12 |
| 2026-03-31 | Sabar Karimah Es | Reporting person | Option exercise | 61,265 | $4.86 |
| 2026-03-31 | Sabar Karimah Es | Reporting person | Open market sale | 61,265 | $30.17 |
| 2026-03-31 | Bergmann Anthony | CHIEF FINANCIAL OFFICER | Option exercise | 25,000 | $3.18 |
| 2026-03-31 | Bergmann Anthony | CHIEF FINANCIAL OFFICER | Open market sale | 25,000 | $30.13 |
| 2025-12-30 | Krasney Karen | EVP, GENERAL COUNSEL | Option exercise | 2,500 | $1.39 |
| 2025-12-19 | DUNBAR GEORGE W JR | Reporting person | Option exercise | 3,000 | $1.39 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 07:47 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-08-24 | 8-K | 2026-08-24 | View on SEC.gov → |
| 2026-08-14 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-13 | 8-K | 2026-08-13 | View on SEC.gov → |
| 2026-07-30 | 8-K | 2026-07-29 | View on SEC.gov → |
| 2026-07-29 | 8-K | 2026-07-29 | View on SEC.gov → |
| 2026-07-14 | 8-K | 2026-07-09 | View on SEC.gov → |
| 2026-06-29 | 4 | 2026-06-25 | View on SEC.gov → |
| 2026-06-29 | 4 | 2026-06-25 | View on SEC.gov → |
| 2026-06-26 | 8-K | 2026-06-26 | View on SEC.gov → |
| 2026-06-24 | 4 | 2026-06-22 | View on SEC.gov → |
| 2026-06-24 | 4 | 2026-06-22 | View on SEC.gov → |
| 2026-06-08 | 8-K | 2026-06-04 | View on SEC.gov → |
Recent news
Headlines about CAPR (Capricor Therapeutics, Inc.). Links open the publisher — we don’t host full articles.
-
MRNA, LNTH, BMY, CAPR, RARE Stocks In Focus — These FDA Decisions Could Shape August Trading
Stocktwits · 2026-10-22 -
CAPR Oct 2026 6.000 put (CAPR261030P00006000) stock price, news, quote and history
Yahoo Finance UK · 2026-10-21 -
CAPR Oct 2026 1.000 call (CAPR261023C00001000) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-21 -
CAPR Oct 2026 5.500 call (CAPR261023C00005500) stock historical prices and data
Yahoo Finance UK · 2026-10-21 -
Capricor Therapeutics, Inc. (CAPR) Stock Price, News, Quote & History
Yahoo Finance · 2026-10-21 -
CAPR Stock on Track For Worst Month Since July AdCom Vote On Deramiocel As November FDA Decision Nears
Yahoo · 2026-10-21 -
CAPR Nov 2026 8.000 call (CAPR261113C00008000) Interactive Stock Chart
Yahoo! Finance Canada · 2026-10-21 -
CAPR Oct 2026 7.500 call (CAPR261030C00007500) stock price, news, quote and history
Yahoo Finance UK · 2026-10-21
No headlines in this category right now — try “All”.